Current Report Filing (8-k)
January 07 2022 - 04:22PM
Edgar (US Regulatory)
0001514946 false false 0001514946
2022-01-04 2022-01-04
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): January
4, 2022
AXIM BIOTECHNOLOGIES,
INC.
(Exact name of registrant as specified in its charter)
Nevada
|
|
000-54296
|
|
27-4092986
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
6191 Cornerstone Court E., Suite 114
San
Diego, California
|
|
92121
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(858)
923-4422
(Registrant’s telephone number, including area code)
(Former name if changed since last report)
|
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the
following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
5.02Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements with Certain Officers
On January 4, 2022, Mauricio Gatto Bellora tendered his resignation
as a member of the Board of Directors of AXIM Biotechnologies, Inc.
(the "Company"), and the Company on that date accepted his
resignation. Mr. Bellora's decision to resign was not the result of
any disagreement with the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
AXIM
BIOTECHNOLOGIES, INC.
|
|
|
|
|
|
|
|
|
Dated:
January 7, 2022
|
|
By:
|
/s/ John W. Huemoeller II
|
|
|
|
Name:
John W. Huemoeller II
|
|
|
|
Chief
Executive Officer
|
Axim Biotechnologies (QB) (USOTC:AXIM)
Historical Stock Chart
From Apr 2022 to May 2022
Axim Biotechnologies (QB) (USOTC:AXIM)
Historical Stock Chart
From May 2021 to May 2022